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Abstract
Background: In patients with melanoma, knowledge of regional lymph node status provides important information on
outlook. Since lymph node status can influence treatment, surgery for sentinel lymph node (SLN) biopsy became a standard
staging procedure for these patients. Current imaging modalities have a limited sensitivity for detection of micrometastases
in lymph nodes and, therefore, there is a need for a better technique that can accurately identify occult SLN metastases.
Methodology/Principal Findings: B16-F10 murine melanoma cells were infected with replication-competent herpes simplex
virus (HSV)NV1023. Thepresence of tumor-targeting and reporter-expressing virus wasassessed by [
18F]-29-fluoro-29-deoxy-1-
b-D-b-arabinofuranosyl-5-ethyluracil ([
18F]FEAU) positron emission tomography (PET) and confirmed by histochemical assays.
An animal foot pad model of melanoma lymph node metastasis was established. Mice received intratumoral injections of
NV1023, and 48 hourslaterwereimagedafter i.v. injectionof [
18F]FEAU.NV1023 successfully infected and provided high levels
of lacZ transgene expression in melanoma cells.Intratumoral injection of NV1023 resulted in viral trafficking to melanoma cells
that had metastasized to popliteal and inguinal lymph nodes. Presence of virus-infected tumor cells was successfully imaged
with [
18F]FEAU-PET, that identified 8 out of 8 tumor-positive nodes. There was no overlap between radioactivity levels (lymph
node to surrounding tissue ratio) of tumor-positive and tumor-negative lymph nodes.
Conclusion/Significance: A new approach for imaging SLN metastases using NV1023 and [
18F]FEAU-PET was successful in a
murine model. Similar studies could be translated to the clinic and improve the staging and management of patients with
melanoma.
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Introduction
Solid tumors including malignant melanoma, breast, head and
neck, gastrointestinal and genitourinary carcinomas are prevalent
cancers worldwide and are a primary cause of mortality in the
Western world [1]. These tumors frequently metastasize to
regional lymph nodes, and lymph node invasion by cancer cells
is one of the most significant factors in predicting prognosis [2].
Even in the absence of clinical or radiologic evidence of lymph
node metastases, the risk for positive regional lymph nodes is
frequently high enough to necessitate lymph node dissection [3].
Surgery for removal of regional lymph nodes is indicated not only
for ablation of cancer, but also for evaluation of the need for
radiation therapy or chemotherapy. The patterns of cancer spread
into lymph nodes are predictable, based on the anatomic location
of the primary tumor. Therefore, a selective surgical procedure is
commonly directed to the basins at risk for lymphatic spread [4].
The morbidity associated with and costs of lymph node dissections
are substantial. Nevertheless, conventional imaging techniques are
unsatisfactory for the evaluation and localization of regional lymph
node metastases due to their limited ability to identify subcenti-
meter micrometastases. Thus, there is a need for an effective
noninvasive modality that can accurately identify occult lymph
node metastases in these patients [5].
Noninvasive reporter gene imaging has been successfully
applied to monitoring gene therapy, including gene delivery and
expression mediated by retroviral [6], adenoviral [7], and
oncolytic herpes viral vectors [8,9,10]. The concept of using
herpes oncolytic viruses and positron emission tomography (PET)
imaging is based on the ability of these vectors to selectively infect
cancer cells and not stromal tissue [11,12]. After entering the cell,
viruses readily express their early genes, among them the herpes
simplex virus (HSV) type 1 (HSV-1)–thymidine kinase (tk) gene
product. As opposed to the mammalian tk-1, the HSV1-tk gene





18F]FEAU, is trapped inside HSV1-tk express-
ing cancer cells; it accumulates in proportion to the level
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4789of HSV1-tk expression and can be imaged using PET
(Figure 1A).
The purpose of this study was to develop a noninvasive method
for the detection of micrometastases in regional lymph nodes using
a replication-competent oncolytic virus carrying the HSV-1-tk
gene. We show, for the first time, that oncolytic viruses introduced
into the lymphatic system via single intratumoral injection can be
used efficiently to detect melanoma micrometastases in regional




The syngeneic malignant melanoma cell line B16-F10 was used
for the in vivo and in vitro experiments. Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
high glucose (HG), 10% fetal calf serum (FCS), 1.5 mmol/L
sodium bicarbonate, 100 mg/L penicillin, and streptomycin. Cells
were maintained in 5% CO2 in a 37uC humidified incubator.
Viruses
NV1023 is an attenuated, replication-competent oncolytic
HSV whose construction was previously described [11]. In brief,
this virus was derived from R7020, an HSV-1 (F9 strain) vector
originally designed as an HSV vaccine. The virus carries a 5.2-kB
fragment of HSV-2 DNA (containing HSV-2 genes US2-2
through US2-5) inserted in the UL/S junction. Attenuation was
achieved by a 15-kB deletion in the inverted repeat region that
extends from the 39 end of UL55 to the promoter for ICP4,
deleting UL56 and 1 copy of the diploid genes ICP0 and ICP4 and
the neurovirulence gene c134.5.T h eEscherichia coli b-galactosi-
dase gene (lacZ) was inserted at the US10-12 locus as an infection
marker.
b-galactosidase assays
Cancer cells were plated at 1610
4 cells per well in 96-well plates
in 100 mL medium. After incubation for 6 hours, NV1023
(500 mL) was added to each well at a multiplicity of infection
(MOI, or the ratio of viral particles per tumor cell) of 0.1.
Expression of the lacZ gene was measured at 24-hour intervals with
an enhanced b-galactosidase assay kit (Gene Therapy Systems,
San Diego, CA) using a spectrophotometer at 570 nm. All samples
were measured in triplicate.
In vivo foot pad model
Animal studies were performed in compliance with all
applicable policies, procedures and regulatory requirements of
the Institutional Animal Care and Use Committee (IACUC), the
Research Animal Resource Center (RARC) of MSKCC and the
National Institutes of Health (NIH) ‘‘Guide for the Care and Use
of Laboratory Animals’’. All animal procedures were performed
by inhalation of 2% isoflurane. After the studies all animals were
sacrificed by CO2 inhalation.
A foot pad syngeneic melanoma model was established as
described previously by Harrell et al [13]. Briefly, 30 6-week-old
C57BL/6J-Tyr
C-2J/J albino mice (Jackson Laboratories, Bar
Harbor, Maine) were anesthetized with inhalational isoflurane
for all procedures. The right hind limb foot pad was sterilized with
alcohol, and then slowly injected with 50 mL of cell suspension at a
concentration of 2610
5 cells/mL over a 2-minute period. The
mice were then awakened and their foot pad monitored for tumor
size and signs of pain or ulceration twice a week. Three to 4 weeks
after tumor injection we could monitor the presence of isolated
black-colored sub centimeter lymph node at the popliteal area, i.e.,
the first echelon lymphatic region of the foot pad. In some animals
there was also evidence for positive lymph nodes in the inguinal
area, the secondary echelon of the foot pad. Only animals with
primary tumors ,5 mm that were confined to the foot pad area
(50% of the animals) were used in the PET imaging study.
NV1023 (1610
7 viral plaque-forming units [PFU]) was injected to
the foot pads bilaterally (both to the tumor and the contralateral
foot pad). Five of the animals with tumors were injected with saline
before [
18F]FEAU/PET imaging and served as a negative control.
Another 5 animals without tumors were injected with NV1023
and the morphology of their lymph nodes was monitored.
Histologic examination confirmed the presence of metastatic
melanoma cells in cases of palpable/black-colored nodes, which
were generally 0.8 mm in dimension at the time of diagnosis.
Metastatic melanoma cells were deposited in the subcapsular sinus
of the lymph node and infiltrated the nodal parenchyma.
[
18F]FEAU PET
The concept of [
18F]FEAU PET imaging with NV1023 is based
on the ability of the HSV-1-tk reporter gene, to catalyze the
phosphorylation of the thymidine analog [
18F]FEAU. Figure 1
depicts the mechanism by which the HSV-1-tk transgene serves as
a molecular marker for the detection of melanoma metastases.
Figure 1. Schematic demonstration of (A) virus infection, replication, transgene expression, and [18F]FEAU PET imaging and (B) in vivo
experimental setup.
doi:10.1371/journal.pone.0004789.g001
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18F]FEAU tracer was synthesized by coupling the radiolabeled
fluoro sugar with the silylated pyrimidine derivative following a
procedure previously reported by Serganova [14]. The specific
activity of the product was ,37 GBq/mmol (,1 Ci/mmol);
radiochemical purity was .95% following purification by high-
performance liquid chromatography (HPLC).
Following virus injection, animals were intravenously injected
with ,250 mCi (9.25 MBq) of [
18F]FEAU tracer 2 hours before
PET imaging was performed. Mice were sacrificed with CO2,
degutted, and immediately imaged with a dedicated small-animal
PET scanner (Focus 120 micro-PET, Concorde Microsystems,
Knoxville, TN). The foot pad of the animals was amputated prior
to imaging to avoid high background levels of radiotracer uptake
in the tumor. In all animals the tumor was localized to the foot pad
and did not infiltrate below the wrist. Images were acquired using
a transaxial field of view of 10 cm and an axial field of view of
7.8 cm. An energy window of 350–750 keV and a coincidence
timing window of 6 nanoseconds were used. The resulting list-
mode data were sorted into 2-dimensional histograms by Fourier
rebinning, and transverse images were reconstructed by filtered
backprojection into a 1286128663 (0.7260.7261.3 mm) matrix.
Image analysis was performed using the ASIPro (Siemens
Preclinical Solutions, Knoxville, TN). After imaging, the popliteal
and inguinal lymph nodes were excised bilaterally, weighed, and
measured for radioactivity (%ID/g) using a gamma counter
(Packard, United Technologies, Downers Grove, IL).
Histochemistry
After the final image, the animals were sacrificed and the lymph
nodes harvested and frozen in Tissue-Tek Optimal Cutting
Temperature (OCT) compound (Sakura Finetek USA, Inc.,
Torrance, CA). Tissues were cut into 5-mm-thick sections and
mounted on glass slides. Cryosections were fixed and lymph nodes
were stained with hematoxylin and eosin (H&E) or 5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside (X-gal) for assessment of
b-galactosidase expression. Cells were stained for 4 hours with X-
gal (1 mg/mL) in an iron solution of 5 mM K4Fe(CN)6,5m M
K3Fe(CN)6, and 2 mM MgCl2, as previously described. Counter-
staining of background cells with nuclear fast red was performed.
Virally infected cells expressing b-galactosidase were identified
histologically as blue-staining cells.
Criteria for lymph node status were based on microscopic
evaluation: a) lymph nodes with melanoma metastases that were
readily identified by the presence of black melanin pigment were
considered positive nodes; and b) lymph nodes that were devoid of
cancer cells were considered negative nodes.
Viral Proliferation
For the viral proliferation studies, 2610
4 cells were seeded per
well in 12-well plates in 1 mL medium. After incubation for
6 hours, NV1023 (100 mL) was added to each well at MOIs of
0.01, 0.1, and 1. Supernatant containing released virus was
collected at day 2 and frozen. Vero cells were grown to confluence
on 6-well plates. Supernatant samples were thawed, and samples
were diluted 10-fold serially. Dilutions were then incubated on
confluent Vero cells for 4 hours. Wells were washed with medium
and covered with 1% agarose in medium. After 48 hours, 2 mL of
neutral red solution (2% by volume) was added, and viral plaques
were counted 24 hours later. Samples were done in triplicate.
Immunoblotting
For expression of b-galactosidase and HSV1TK, cells were
grown in 6 well plates. Forty-eight hours after infection with
NV1023 at MOIs of 0.01, 0.1 and 1, cells were released without
enzymatic digest at 4uC. Cell pellets were sonicated for 10 seconds
and clarified by centrifugation. Total protein (50 mg) underwent
electrophoresis in 7.5% Tris-HCl gels (Bio-Rad, Hercules, CA)
and was transferred to polyvinylidene difluoride membranes,
blocked and exposed to primary antibody followed by a secondary
antibody conjugated to horseradish peroxidase. Bands were
developed using an ECL Plus detection system (Amersham,
Piscataway, NJ). Density was quantified using a computer-
controlled CCD camera (AlphaImager Imaging Systems, Alpha
Innotech, San Legndra, CA). The following antibodies were used:
b-actin, HSV1-TK and b-galactosidase (Santa Cruz Biotech,
Santa Cruz, CA)
Statistical Analysis
Student t tests or analyses between groups were used for
statistical analysis as appropriate. Differences were considered
significant at P,0.05. All data is represented as mean6SD, unless
otherwise indicated. All experiments were repeated in triplicate.
Data from representative experiments are shown.
Results
Time course of NV1023 infection
We first evaluated the ability of NV1023, a replication-
competent HSV, to infect malignant melanoma cells in vitro using
a viral amplification assay. Cells were infected with NV1023 at
MOIs of 0.01–1 and viral titers measured at 48 hours. NV1023
demonstrated highly efficient replication in B16-F10 melanoma
cells within 48 hours after infection. As shown in Figure 2A,
melanoma cells strongly supported viral proliferation, with an
approximately 100-fold increase in viral titer from MOI of 0.01
to 1.
The Escherichia coli b-galactosidase transgene (lacZ), inserted at
the US10-12 locus of the NV1023 virus, was used as an infection
marker. The ability of NV1023 to infect B16-F10 melanoma cells
was studied in vitro during a 3-day period. The expression of the
lacZ gene increased more than 13-fold during the first 48 hours
after inoculation and decreased 72 hours after infection
(Figure 2B). Western blotting analysis performed 48 hours after
viral infection at MOIs of 0.01–1 revealed that expression of b-
galactosidase was correlated with HSV1-tk expression in melano-
ma cells (Figure 2C). Based on this data, we postulated that the
optimal time for imaging of virus infection would be approxi-
mately 48 hours after inoculation.
Identification of lymph nodes with melanoma metastases
and expression of viral proteins
Malignant melanoma tumors were established in the right foot
pad of 30 C57BL/6J-Tyr
C-2J/J albino mice by direct injection of
2610
5 melanoma cells (B16-F10). Twenty days after cancer cell
injection, approximately 50% of the animals had evidence of
subcentimeter black-colored lymph nodes in their popliteal area
(Figure 3).
Histopathologic analysis was used to define positive (with
melanoma metastases) and negative (no tumor cells) lymph nodes.
The presence of NV1023 in sentinel lymph nodes with melanoma
micrometastases was verified based on expression of the lacZ
transgene. LacZ staining after NV1023 infection in vitro revealed
cytoplasmatic expression of b-galactosidase (Figure S1). However
melanoma metastatic cells in lymph nodes had dark pigmented
cytoplasm, and it was difficult to see the light blue lacZ staining in
the cells. Yet, by analyzing whole specimens of lymph nodes with
metastases, we found diffuse accumulation of lacZ staining only in
areas with metastatic melanoma cells (Fig 4A–C). In contrast,
Imaging Lymph Node Metastases
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mice injected with NV1023, we noticed only light and non-specific
staining of lacZ (Fig 4D). Similarly, positive lymph nodes treated
with saline had no lacZ staining.
[
18F]FEAU PET imaging with NV1023 allows detection of
sentinel lymph node metastases in vivo
We randomly selected 5 of the tumor bearing animals for the
test group. These mice were injected with 1610
7 PFU of NV1023
into the tumor-bearing and non tumor-bearing foot pads. In a
second group of tumor-bearing mice (n=5), the foot pads were
injected with saline alone. This group served as a negative control.
Two days after viral or saline injection, all mice received an
intravenous injection of [
18F]FEAU (250 mCi).
Region of interest (ROI) measurements from [
18F]FEAU PET
scans in mice injected with NV1023 identified all tumor-positive
lymph nodes (with melanoma metastases) (n=8). Conversely, all
tumor-negative lymph nodes in mice injected with NV1023 (n=5)
and mice treated with saline (n=5) had [
18F]FEAU signal levels
similar to background (Figure 5). The lymph node-to-surround-
ing tissue radioactivity ratio was significantly higher (P,0.001) for
tumor-positive lymph nodes compared to tumor-negative nodes.
Nucleoside analogs are not accumulated or trapped by mamma-
lian tissue, as only virus-containing cells can induce phosphory-
lation of these tracers by the HSV1-tk reporter gene [8,15,16,17].
Figure 5 shows a representative experiment of [
18F]FEAU uptake
in an animal with a lymph node metastasis injected with saline.
The figure clearly demonstrates no radiotracer accumulation by
mammalian tissue, aside from gallbladder uptake, where colonies
of thymidine kinase forming bacteria may augment the back-
ground signal.
Immediately after imaging, the lymph nodes were excised,
weighed and radioactivity analyzed in a gamma counter prior to
histological examination. There was a clear separation in
Figure 2. In vitro b-galactosidase and HSV-1TK transgene expression over time. (A) Viral amplification assay. Cells were infected with
NV1023 at MOIs of 0.01–1 and viral titers measured at 48 hours. NV1023 demonstrated highly efficient replication in B16-F10 melanoma cells within
48 hours after infection. (B) b-galactosidase activity in B16-F10 melanoma cells at 24, 48, and 72 hours after infection with NV1023. (C) Western
blotting analysis performed 48 hours after viral infection at MOIs of 0.01–1 revealed that expression of b-galactosidase was correlated with HSV1-tk
expression in melanoma cells.
doi:10.1371/journal.pone.0004789.g002
Figure 3. In situ photograph of lymph node metastasis from
melanoma. B16-F10melanoma cells were injected intothe right footpad
of C57BL/6J-TyrC-2J/J mice. Twenty days after cancer cell injection,
melanoma metastases were detected in the right popliteal area.
doi:10.1371/journal.pone.0004789.g003
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tumor-negative (n=20) nodes with no overlap (Figure 6B). All
positive lymph nodes had radioactivity values at least two standard
deviations above the negative nodes. The radioactivity level profile
is similar to that obtained from the ROI analysis of the microPET
images (Figure 6).
Although statistical analysis revealed that the weight of tumor-
positive nodes was significantly larger than tumor-negative nodes
(0.02360.006 and 0.01560.006, respectively, P,0.05), the weight
of 7 out of 8 positive nodes was in the range of the negative nodes
(0.007–0.029 mg). This shows that NV1023-PET imaging system
can identify tumor-positive lymph nodes within the range of
‘normal’ size lymph nodes, which is not the case with conventional
imaging methods.
Discussion
The standard of care for patients with intermediate and
advanced stage melanoma is resection of the primary tumor with
excision of first echelon lymph nodes that receive lymphatic
drainage from the tumor [18]. Lymphoscintigraphy and SLN
biopsy are used for staging of melanoma as well as other
carcinomas [19,20]. Currently, the search for SLN is performed
either by use of blue dye injection into tumors resulting in the
coloring of the draining nodes, or by injection of technetium-99m-
labeled nanocolloid and localization of nodes by combining
preoperative lymphatic mapping and intraoperative gamma probe
detection [21]. These modalities for SLN mapping require surgery
and pathologic analysis of the excised lymph nodes. The presence
of metastases in one or more lymph nodes usually requires further
treatment, which may include a second surgery, radiotherapy,
immunotherapy, chemotherapy, or combination treatment [22].
In other mucosal tumors such as gastrointestinal and genitourinary
carcinomas, tumors are not easily accessible for injection and
lymph nodes are difficult to biopsy. Since occult lymph node
metastases are common and have a major impact on survival,
patients would benefit significantly from a noninvasive method
that would allow accurate detection of lymph nodes invaded by
cancer [2].
The imaging modalities used in clinical practice today for nodal
staging include ultrasound, contrast-enhanced computed tomog-
raphy, contrast-enhanced magnetic resonance imaging (MRI), and
[
18F]FDG PET scanning. Ultrasound, computer tomography and
magnetic resonance imaging relay mainly on lymph node size.
None of these methods can reliably detect subcentimeter lymph
nodes with micrometastases [23,24,25].
Historical studies have shown that wild-type HSV-1 possesses a
natural tropism for infecting tumor tissues [26]. Recent studies by
our group and others have observed that oncolytic HSV-1
demonstrates a strong selectivity for infecting cancer cells
including malignant melanoma cells [11,12,27,28,29,30]. Al-
though these viruses were not specifically designed to target
malignant tumors, we have repeatedly observed that they display a
remarkable selectivity for infecting malignant cells over normal
cells [31,32,33]. This was also described in phase I studies for
treatment of patients with malignant melanoma [34,35]. The
selective infection of cancer cells with oncolytic HSV was recently
evaluated in our laboratory in association with normal stromal
Figure 4. Histologic analysis of lymph nodes after imaging showing metastatic and normal lymph nodes from mice injected with
NV1023. (A) LacZ staining (blue) shows diffuse b-galactosidase transgene expression adjacent to metastatic B16-F10 melanoma cells (black cells,
scale bar 30 mm). The white arrow indicates the area of micrometastases. (B) High magnification of the area in (A) indicated by the arrow showing
diffuse LacZ staining in the area of metastases (scale bar 10 mm). (C) High magnification of a positive lymph node showing non-specific LacZ stain in
an area devoid of melanoma cells. (D) Low magnification of a normal lymph node from an animal treated with NV1023. Only a non-specific LacZ
staining is seen (scale bar 130 mm).
doi:10.1371/journal.pone.0004789.g004
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normal stroma was detected in vitro and in vivo up to 7 days after
infection [28].
Reporter gene imaging with HSV1-tk has been used extensively
in animal models of cancer. The expression of HSV1-tk can be
imaged and monitored using specific radiolabeled substrates that
are selectively phosphorylated by HSV1-tk and trapped within
transfected cells. Three radiotracers that are widely used by many







18F]FHBG) [14,36,37,38,39,40]. HSV1-tk–expressing bac-
teria have recently been shown to localize in various tumors,
including B16-F10 murine melanoma cells, and primary tumors
were successfully imaged with [
124I]FIAU or [
18F]FEAU [41,42].
In a previous paper [8], we have shown that at 48 hours after
[
124I]FIAU administration, saline-treated tumors demonstrated a
mean [
124I]FIAU accumulation of 0.002160.0002 percent dose/g
tissue, whereas tumors treated with 1610
7 p.f.u. of NV1020
demonstrated a mean accumulation of 0.004760.0004 percent
dose/g (P,0.0002, n=9 in each group). Similarly, tumors treated
with 5610
7 p.f.u. of NV1020 demonstrated a mean accumulation
of 0.007060.0009 percent dose/g (P,0.0002, n=9). The
specificity and efficacy of [
18F]FEAU imaging using NV1023/
HSV1-tk reporter gene was recently demonstrated by our group
for various other tumors [28].
Figure 5. [
18F]FEAU-PET imaging of mice with and without positive lymph node metastases. Representative coronal views of (A) a control
animal with positive SLN injected with saline and (B) a mouse without tumor injected with NV1023, showing accumulation of radioactive signals in
the gut, gallbladder and bladder. (C) A coronal view of a mouse with positive popliteal and inguinal lymph node metastases injected with NV1023.
Positive PET signal was detected only in positive lymph nodes (white arrows). (D) The lymph node-to-surrounding tissue radioactivity ratios were
measured in the PET scans; negative lymph nodes (blue column, n=10), positive lymph nodes (orange column, n=8).
doi:10.1371/journal.pone.0004789.g005
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metastases using an oncolytic HSV/NV1023 and reporter gene
imaging. Using NV1023 as the delivery vector, we demonstrate
that a single injection of this attenuated, replication-competent
virus into the primary tumor will induce expression of HSV1-tk in
cancer cells invading lymph nodes that can be selectively imaged
with [
18F]FEAU PET. This imaging system was sensitive and
accurate enough to detect micrometastases in lymph nodes that
measured ,3 mm in diameter. In one tumor-positive lymph node,
the lymph node-to-surrounding tissue radioactivity ratio was close
to unit, 1.5. This low ratio was primarily due to the high level of
background radioactivity that surrounded this lymph node. This
illustrates the importance of imaging when background radioac-
tivity is low [43]. This imaging paradigm is capable of
distinguishing between normal nodes and those infiltrated by
cancer as early as 48 hours after viral injection. Although the
sensitivity of this imaging paradigm (minimal number of tumor
cells per node that are detectable) was not determined in this
study, a significantly higher uptake and retention of [
18F]FEAU
was detected in all nodes invaded by cancer compared to non
invaded normal nodes (.2 standard deviations).
Lymph node size may be correlated to immune infiltrates and
not only to metastatic volume. We demonstrated that although
tumor invaded lymph nodes were slightly heavier than normal
nodes, the majority of lymph node with metastases (7 out of 8)
were within the weight range of normal nodes. This suggests that
lymph node weight alone can not predict the presence tumor
micrometastases, and that NV1023-PET imaging system can
identify tumor-positive lymph nodes within the range of ‘normal’
size lymph nodes, which is not the case with conventional imaging
methods.
Studies have implicated the ability of oncolytic viruses,
including HSV-1, to be effectively transported into the lymphatic
circulation [44,45,46,47,48,49,50]. Herpesviral particles are
125 nm in diameter, and theoretically they can travel through
the lymphatic system in the same fashion that malignant cells
metastasize to regional lymph nodes. Injection of NV1023 viruses
into normal skin was shown to result in viral transit to normal
cervical lymph nodes [50]. In the absence of metastatic disease,
NV1023 infection of normal cells within the lymph nodes was
sparse and demonstrated rapid clearance from the lymphatic
system [50]. However, in the presence of metastatic cells, viruses
could be detected for several days after injection [47,50].
Interestingly, herpesvirus may also travel to the lymph nodes
within leukocytes or Langerhans cells [51], permitting viral
replication and subsequent infection of nodal tumor cells. In
addition, it is theoretically possible that residual melanoma cells at
the primary tumor site may have been locally infected with virus,
dislodged, and subsequently passed to the sentinel lymph nodes. It
is also possible that both tumor cells and lymphocytes are being
transduced in vivo. Nevertheless, in all three putative mechanisms,
the end result would be selective expression of viral genes in
positive lymph nodes [49,52,53].
Gene expression imaging of occult lymph node metastases was
recently described by Burton et al. for direct PET visualization of
prostate cancer [54]. In this study they used a prostate-specific




[55]. Peritumoral administration of this vector enabled direct
detection of reporter gene expression in metastatic lesions within
the lymph nodes. Detection of lymphatic metastases was
previously described using oncolytic viruses carrying eGFP
[45,52,56] or Renilla luciferase reporter genes [56]. In another
study PET [
18F]FEAU with HSV-1 oncolytic viruses was shown to
enhance the detection of nerves infiltrated by cancer cells using
noninvasive imaging [28].
None of the NV1023-treated animals suffered from clinically
apparent side effects attributable to viral administration. The
parent virus from which NV1023 was derived, R7020, has a very
favorable safety profile in Aotus owl monkeys, a primate exquisitely
sensitive to herpes viral infections [57]. Even at a 10,000-fold
higher dose than wild-type HSV-1, R7020 remained less toxic to
Aotus monkeys compared with HSV-1. A similar virus, NV1020,
was recently studied in a phase I trial for patients with hepatic
colorectal metastases. Doses of #1.3610
9 PFU were administered
by hepatic infusion pump without dose-limiting toxicity or
significant adverse events attributable to the virus [58]. NV1020
has a highly favorable safety profile, a finding that has encouraged
our investigation of related vectors such as NV1023 for clinical
application.
One potential diagnostic application of this viral-imaging
paradigm is the staging of disease and guiding future treatment.
In melanoma, head and neck, and breast carcinomas, imaging the
targets of replication-competent viruses could be performed
following a single intratumoral injection. In mucosal tumors such
as gastrointestinal and genitourinary carcinomas, NV1023 or
similar vectors can be delivered through endoscopic injections to
intraluminal primary tumors [59]. Imaging of HSV-1-TK
expression could then be visualized using a conventional PET
imaging system to identify lymph nodes which harbor malignant
cells. The ability of this method to detect micrometastases within
SLN is likely to be better than conventional imaging techniques
that require assessment of lymph node volume and non-contrast
filling regions in the lymph nodes [60].
The high background signal in our system required amputation
of the primary tumor and degutting of the animals previous to
imaging. This problem may question the feasibility of HSV1-TK/
Figure 6. Radioactivity measurements and lymph node weight.
(A) Lymph node-to-surrounding tissue radioactivity ratios obtained
from the [
18F]FEAU PET images in NV1023-treated animals versus lymph
node weight (8 positive nodes (¤) R2=0.603; y= 74.0x+0.939 and 10
negative nodes (n) R2=0.035; y=2.62x+1.080). (B) Ex vivo radioactivity
measurements from excised lymph nodes. Lymph node radioactivity
(%ID/g) in NV1023-treated animals versus lymph node weight (8
positive nodes (¤) R2=0.328; y=14.4x+0.214 and 20 negative nodes
(n) R2=0.054; y=21.40x+0.108).
doi:10.1371/journal.pone.0004789.g006
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18F]FEAU imaging tool for diagnostic staging. In several human
PET studies using nucleoside analogs and in our laboratory it was
found that intestinal background uptake does not play an important
role in patients (Brader and Blasberg unpublished data, [61,62]. In
addition,the relatively large distanceof locoregional lymph nodes at
the head and neck, axillary or popliteal regions from the intestines
could furtherimprovethe signalto noise ratio in a clinical setting. In
order to further reduce the radioactive background signal at the
intestines, we are currently exploring different strategies to increase
fecal elimination of radiotracer in a preclinical setting.
Conclusions
Our study shows that the NV1023 herpes virus expressing the
HSV-1-tk gene can track to draining lymph nodes following direct
intratumoral injection and infect metastatic melanoma cells in the
SLNs. Nodal metastases can be then successfully identified by
[
18F]FEAU PET imaging. The findings are encouraging and
translation to the clinic is feasible. If successfully implemented, this
imaging system has the potential for improving patient care by
enabling: (1) a more sensitive noninvasive method for the detection
of lymph nodes invaded by cancer, (2) delineation of the extent
and anatomic location of regional metastases (3), provide better
pre-surgical assessment of disease extent in patients with suspected
positive lymph nodes and (4) provide guidance for adjuvant
radiotherapy, immunotherapy, or chemotherapy to patients with
lymph node metastases.
Supporting Information
Figure S1 LacZ staining 48 hours after NV1023 infection in
vitro revealed cytoplasmatic expression of beta-galactosidase.
Found at: doi:10.1371/journal.pone.0004789.s001 (0.42 MB TIF)
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